Skip to the answer

Maraviroc

Maraviroc is an antiviral medication used in combination with other HIV drugs to treat CCR5-tropic HIV-1 infection in adults and children.

Brand name Selzentry
Drug class Ccr5 Co-receptor Antagonist
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 11 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

Maraviroc at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Maraviroc (Selzentry) is a specialist HIV medicine that blocks CCR5, a doorway HIV-1 uses to enter immune cells, so it only works for CCR5-type virus confirmed by a tropism blood test; around since about 2007 and available as a generic, it is always combined with other HIV drugs, most often after other regimens have failed or not been tolerated. Most people tolerate it fairly well, with colds, cough, dizziness or an upset stomach the usual complaints. The boxed warning is liver damage, which can begin with a severe rash or fever, so yellowing skin or eyes, dark urine or a new rash means seeking care right away.

Clinical pearls

  • Your dose depends on your other medicines, so new antibiotics, antifungals, seizure drugs or HIV drug changes need a dose check.
  • Avoid St. John's wort, because it can lower maraviroc levels enough to make it less effective against HIV.
  • Get up slowly from sitting or lying, since maraviroc can drop your blood pressure on standing and make you lightheaded.
  • Expect liver blood tests before starting and during treatment, with closer checks if you also have hepatitis B or C.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Serious liver damage (hepatotoxicity) has been reported with maraviroc. In some cases, it was preceded by a severe skin rash or signs of a systemic allergic reaction — such as fever, high levels of certain immune cells (eosinophilia), or elevated allergy antibodies (IgE). If you develop a rash, yellowing of the skin or eyes, dark urine, stomach pain, or any signs of an allergic reaction while taking maraviroc, seek medical attention immediately. Do not wait to see if symptoms go away on their own.

Read the full warning on DailyMed →
How you get itPrescription only
Comes asTablet
Earliest FDA record2007
Companies listing it with the FDA8
FDA label last updatedSep 26, 2022
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Maraviroc, written from its FDA label.

What Maraviroc is used for

▾

Maraviroc is an antiviral used in combination HIV treatment. It is approved for the following:

  • Treatment of CCR5-tropic HIV-1 infection in adults — available as Selzentry tablets, Selzentry oral solution, and generic Maraviroc tablets
  • Selzentry (tablet and oral solution) is approved for pediatric patients weighing at least 2 kg, from birth onward
  • Maraviroc tablets (generic) are approved for pediatric patients aged 2 years and older weighing at least 10 kg
  • Always used in combination with other antiretroviral medications — never as a standalone HIV treatment
  • Not recommended for dual/mixed- or CXCR4-tropic HIV-1; a tropism test must be done before starting

How Maraviroc works

▾

HIV-1 needs to attach to a protein called the CCR5 receptor on the surface of certain immune cells in order to get inside and replicate. Maraviroc is a CCR5 co-receptor antagonist — it binds to and blocks that receptor, essentially locking the door so the virus cannot enter. This reduces the viral load (amount of HIV in the blood) and helps preserve immune function over time.

Because maraviroc only works against CCR5-tropic HIV (the strain that uses the CCR5 receptor), it will not be effective against strains that use a different receptor (CXCR4-tropic) or strains that use both (dual/mixed-tropic). That's why testing to confirm the type of HIV is required before treatment begins.

Maraviroc dosage

▾

Maraviroc is taken by mouth twice daily. Both the tablet and oral solution forms can be taken with or without food, though a high-fat meal can notably reduce absorption of the Selzentry oral solution. The right dose depends heavily on which other HIV medications you are taking — some drugs raise or lower maraviroc levels significantly, so your prescriber will set the dose based on your full regimen. Never adjust the dose on your own; always follow your prescriber's and pharmacist's instructions, and check with them before starting or stopping any other medications.

  • Tablets (Selzentry and generic Maraviroc): twice daily by mouth, with or without food
  • Selzentry oral solution: twice daily by mouth, with or without food; note that a high-fat meal can significantly reduce how much is absorbed
  • Dose adjustment may be required in adults with kidney impairment — discuss with your prescriber

Dosing details from the FDA-approved label

From the Maraviroc prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Adults taking potent CYP3A inhibitors (with or without a potent CYP3A inducer), including protease inhibitors (except tipranavir/ritonavir), clarithromycin, cobicistat, elvitegravir/ritonavir, itraconazole, ketoconazole, nefazodone, telithromycin
    • 150 mg twice daily
    • Taken by mouth with or without food; must be given in combination with other antiretroviral medications
  • Adults taking noninteracting concomitant medications (NRTIs, tipranavir/ritonavir, nevirapine, raltegravir, dolutegravir, enfuvirtide, and other drugs that are not potent CYP3A inhibitors or inducers)
    • 300 mg twice daily
    • Taken by mouth with or without food; must be given in combination with other antiretroviral medications
  • Adults taking potent and moderate CYP3A inducers (without a potent CYP3A inhibitor), including efavirenz, carbamazepine, etravirine, phenobarbital, phenytoin, rifampin
    • 600 mg twice daily
    • Taken by mouth with or without food; must be given in combination with other antiretroviral medications
  • Pediatric patients weighing at least 2 kg
    • Administered twice daily
    • Dosage based on body weight (kg) and concomitant medications
    • Maximum: Should not exceed the recommended adult dose
    • Tablets for aged 2 years and older weighing at least 10 kg; if a child cannot reliably swallow tablets, prescribe the oral solution
  • Patients with renal impairment
    • Dose adjustment may be necessary in adult patients with renal impairment
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION • Prior to initiation of Maraviroc for treatment of HIV-1 infection, test all patients for CCR5 tropism using a highly sensitive tropism assay. ( 2.1 ) • Maraviroc tablets are taken twice daily by mouth and may be taken with or without food. Maraviroc must be given in combination with other antiretroviral medications. ( 2.2 ) Recommended Dosage in Adult Patients: ( 2.3 ) Concomitant Medications Dosage of Maraviroc When given with potent cytochrome P450 (CYP)3A inhibitors (with or without potent CYP3A inducers) including PIs (except tipranavir/ritonavir) ( 2.3 , 7.1 ) 150 mg twice daily With NRTIs, tipranavir/ritonavir, nevirapine, raltegravir, and other drugs that are not potent CYP3A inhibitors or CYP3A inducers ( 2.3 , 7.1 ) 300 mg twice daily With potent and moderate CYP3A inducers including efavirenz (without a potent CYP3A inhibitor) ( 2.3 , 7.1 ) 600 mg twice daily A more complete list of coadministered drugs is listed in Dosage and Administration. ( 2 ) Recommended Dosage in Pediatric Patients 2 years and older and weighing at Least 10 kg: Administer twice daily. Dosage should be based on body weight (kg) and concomitant medications and should not exceed the recommended adult dose. ( 2.4 ) Recommended Dosage in Patients with Renal Impairment: Dose adjustment may be necessary in adult patients with renal impairment. ( 2.5 ) 2.1 Testing prior to Initiation of Maraviroc Prior to initiation of Maraviroc for treatment of HIV-1 infection, test all patients for CCR5 tropism using a highly sensitive tropism assay. Maraviroc is recommended for patients with only CCR5-tropic HIV-1 infection. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on Maraviroc [see Microbiology (12.4) , Clinical Studies (14.1) ]. Monitor patients for alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin prior to initiation of Maraviroc and at other time points during treatment as clinically indicated [see Warnings and Precautions (5.1) ]. 2.2 General Dosing Recommendations Maraviroc tablets are taken twice daily by mouth and may be taken with or without food. Maraviroc must be given in combination with other antiretroviral medications.

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Maraviroc side effects

▾

The most commonly reported side effects with maraviroc include:

Common side effects

  • Upper respiratory tract infections (colds, sinus infections)
  • Cough
  • Fever
  • Rash
  • Dizziness or lightheadedness
  • Nausea, vomiting, or stomach upset
  • Diarrhea
  • Trouble sleeping
  • Joint or muscle pain

When to get medical help

  • Get medical help right away if you develop yellowing of your skin or eyes, dark urine, or severe stomach pain — these can be signs of liver damage (hepatotoxicity)
  • Seek care immediately if you get a severe rash, especially with fever, blisters, mouth sores, or swollen face — this could be a life-threatening allergic reaction (including Stevens-Johnson syndrome)
  • Call your doctor if you feel faint, dizzy, or lightheaded when you stand up — this may signal low blood pressure (postural hypotension)
  • Tell your doctor right away if you experience chest pain, shortness of breath, or other signs of a heart problem
  • Watch for signs of infection — especially symptoms of pneumonia, herpes, or other unusual illnesses — and report them promptly
  • Tell your doctor about any new or worsening symptoms, as your immune system may react to hidden infections as it recovers (immune reconstitution syndrome)

Serious reactions — including liver damage, severe skin reactions, and cardiovascular events — have also been reported. Seek medical attention right away if you develop jaundice (yellowing of skin or eyes), a blistering rash, chest pain, or signs of a severe allergic reaction.

Maraviroc warnings and precautions

▾
  • Liver damage (hepatotoxicity): Serious and potentially life-threatening liver damage has been reported. It may come on with a severe rash or allergic reaction. Watch for yellowing of the skin or eyes, dark urine, or belly pain — and get medical care immediately if these occur.
  • Severe skin and allergic reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Stop maraviroc immediately and seek care if you develop a severe rash, blisters, mouth sores, or facial swelling.
  • Heart events: A higher rate of myocardial ischemia (reduced blood flow to the heart) and heart attack was observed in treatment-experienced patients receiving maraviroc. People with pre-existing heart disease or risk factors should be monitored closely.
  • Low blood pressure (postural hypotension): Dizziness or fainting when standing can occur, particularly in people with severe kidney disease. Dose reduction may be needed in some cases.
  • Immune reconstitution syndrome: As your immune system recovers, it may react to hidden infections, causing new or worsening symptoms. Tell your doctor about any new symptoms after starting treatment.
  • Potential infection risk: Because maraviroc affects a receptor on immune cells, there is a possible increased risk of certain infections, including herpes virus infections.
  • Potential malignancy risk: There is a theoretical risk of increased cancer risk due to the drug's mechanism; long-term monitoring is recommended.

Maraviroc interactions

▾

Maraviroc's level in your blood can be significantly raised or lowered by other medications, which directly affects both its effectiveness and safety. Key interactions include:

  • CYP3A inhibitors (e.g., most HIV protease inhibitors, clarithromycin, ketoconazole, itraconazole, cobicistat): These increase maraviroc blood levels — a lower dose of maraviroc is required when taken together
  • CYP3A inducers (e.g., efavirenz, rifampin, carbamazepine, phenytoin, phenobarbital, etravirine): These decrease maraviroc levels — a higher dose may be required to maintain effectiveness
  • St. John's Wort: This herbal supplement can substantially lower maraviroc levels, potentially causing treatment failure and drug resistance — avoid while taking maraviroc
  • Tipranavir/ritonavir: Unlike most other protease inhibitors, this combination does not require a maraviroc dose reduction and is treated as a noninteracting medication for dosing purposes

Interactions listed in the FDA-approved label

From the Maraviroc prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • CYP3A inhibitors, including protease inhibitors (except tipranavir/ritonavir): Coadministration will increase the concentration of maraviroc. A dosage adjustment may be required; see Dosage and Administration (2.3, 2.4).
  • CYP3A inducers, including efavirenz: Coadministration may decrease the concentration of maraviroc. A dosage adjustment may be required; see Dosage and Administration (2.3, 2.4).
  • St. John's wort (Hypericum perforatum) or products containing St. John's wort: Coadministration is expected to substantially decrease maraviroc concentrations and may result in suboptimal levels of maraviroc, loss of virologic response and possible resistance to maraviroc. Concomitant use is not recommended.
  • Inhibitors and inducers of P-glycoprotein (P-gp): The pharmacokinetics of maraviroc are likely to be modulated by inhibitors and inducers of CYP3A and P-gp. A dosage adjustment may be required.
  • Inhibitors of OATP1B1 and MRP2: The pharmacokinetics of maraviroc may be modulated by inhibitors of OATP1B1 and MRP2. A dosage adjustment may be required.
Read the label’s full interactions text

7 DRUG INTERACTIONS • Coadministration with CYP3A inhibitors, including protease inhibitors (except tipranavir/ritonavir), will increase the concentration of maraviroc. ( 7.1 ) • Coadministration with CYP3A inducers, including efavirenz, may decrease the concentration of maraviroc. ( 7.1 ) • Coadministration with St. John’s wort is not recommended. ( 7.1 ). 7.1 Effect of Concomitant Drugs on the Pharmacokinetics of Maraviroc Maraviroc is metabolized by CYP3A and is also a substrate for P-glycoprotein (P-gp), organic anion-transporting polypeptide (OATP)1B1, and multidrug resistance-associated protein (MRP)2. The pharmacokinetics of maraviroc are likely to be modulated by inhibitors and inducers of CYP3A and P-gp and may be modulated by inhibitors of OATP1B1 and MRP2. Therefore, a dosage adjustment may be required when maraviroc is coadministered with those drugs [ see Dosage and Administration ( 2.3 , 2.4 ) ]. Concomitant use of maraviroc and St. John's wort ( Hypericum perforatum ) or products containing St. John's wort is not recommended. Coadministration of maraviroc with St. John's wort is expected to substantially decrease maraviroc concentrations and may result in suboptimal levels of maraviroc and lead to loss of virologic response and possible resistance to maraviroc. Additional drug interaction information is available [ see Clinical Pharmacology ( 12.3 ) ].

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿168 supplements and herbs with documented Maraviroc interactions, ranked by severity Check Maraviroc against a supplement or herb →

Before taking Maraviroc

▾
  • A CCR5 tropism test is required before starting maraviroc — it only works against CCR5-tropic HIV-1
  • Tell your doctor if you have liver disease or are co-infected with hepatitis B or C — additional monitoring is needed
  • Tell your doctor if you have kidney disease — dose adjustment may be needed in adults with significant kidney impairment; maraviroc is contraindicated in people with severe kidney impairment or end-stage renal disease who are also taking potent CYP3A inhibitors or inducers
  • Tell your doctor if you have heart disease or cardiovascular risk factors — additional monitoring may be warranted
  • Pregnancy: Discuss with your doctor; a pregnancy registry exists for monitoring outcomes (APR, 1-800-258-4263)
  • Breastfeeding: Do not breastfeed while taking maraviroc — HIV can be transmitted through breast milk
  • Children: Selzentry is approved from birth (weight ≥ 2 kg); generic maraviroc tablets are approved for children aged 2 and older weighing at least 10 kg; children who cannot swallow tablets should use the Selzentry oral solution
  • Older adults: Use with caution; reduced kidney and liver function common in this group may increase the risk of side effects

Maraviroc overdose

▾

The highest single dose tested in clinical trials was 1,200 mg, and the main concerning effect at high doses was postural hypotension (low blood pressure when standing). There is no specific antidote for a maraviroc overdose. If an overdose is suspected, supportive care should be sought — this includes lying flat, monitoring vital signs and heart rhythm, and medical evaluation. Activated charcoal may help reduce absorption if taken shortly after the dose; hemodialysis is not effective at removing maraviroc from the body.

What Maraviroc does in the body

▾

Maraviroc works by blocking the CCR5 receptor on immune cells, preventing CCR5-tropic HIV-1 from attaching and entering those cells. Higher maraviroc blood levels (trough concentrations) are associated with better viral suppression — meaning more of the virus is kept under control. In clinical studies, maraviroc did not meaningfully affect the heart's electrical activity (QT interval) at recommended doses, which is reassuring from a cardiac safety standpoint.

How your body processes Maraviroc

▾

After an oral dose, maraviroc is absorbed within 0.5 to 4 hours, though how much actually reaches the bloodstream (bioavailability) is relatively modest and varies with dose. The drug is about 76% bound to proteins in the blood and is widely distributed throughout the body. Maraviroc is broken down primarily by the liver enzyme CYP3A4 into inactive metabolites, and is eliminated mainly through the feces (about 76%) with a smaller portion in the urine (about 20%). The half-life — the time it takes for the body to clear half the drug — is approximately 14 to 18 hours at steady state. Because high-fat meals can significantly reduce absorption of the oral solution form (but have a more modest effect on the tablet), patients using the Selzentry oral solution should be aware of potential food interactions.

How to store Maraviroc

▾

stored at 20 o C to 25 o C (68 o F to 77 o F); excursions permitted between 15 o C and 30 o C (59 o F and 86 o F) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

168

Supplements & herbs that interact with Maraviroc

168 supplements and herbal products have documented interactions with Maraviroc in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 6
  • Moderate · 124
  • Minor · 38
ACTIVATED CHARCOAL Major BEER Major GRAPEFRUIT Major SIBERIAN COCKLEBUR Major ST. JOHN'S WORT Major WINE Major ACACIA RIGIDULA Moderate ADRAFINIL Moderate +160 more
Every supplement checked against Maraviroc — ranked by severity The full interaction hub: 6 major · 124 moderate · 38 minor · every one linked to its full report. Check Maraviroc against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Maraviroc: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Maraviroc — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is maraviroc treating — is it a cure for HIV?

▾
Maraviroc is not a cure for HIV. It's an antiviral medication that helps control CCR5-tropic HIV-1 by blocking the virus from entering your immune cells. When taken consistently as part of a combination regimen with other HIV medications, it helps keep the virus at low or undetectable levels in your blood — which protects your immune system and reduces the risk of HIV-related illness. You'll need to take it long-term as prescribed.

Why do I need a test before I can even start this medication?

▾
Maraviroc only works against one specific type of HIV called CCR5-tropic HIV-1. Some people have a strain that uses a different receptor (CXCR4-tropic) or one that uses both — and maraviroc won't help against those strains. The tropism test checks which type of HIV you have, so your doctor can confirm maraviroc is the right choice for you before you start. It's a standard step, not a complication.

Can I take maraviroc with food, or does it need to be on an empty stomach?

▾
If you're taking the tablet form (Selzentry or generic maraviroc), you can take it with or without food — food doesn't have a big impact on how the tablet works. If you're using the Selzentry oral solution, be aware that a high-fat meal can significantly reduce how much of the medication your body absorbs. In the clinical trials, there were no strict food restrictions, but talk to your pharmacist or prescriber about how to time your doses with meals, especially if you're on the liquid form.

What side effects should I actually be worried about versus just putting up with?

▾
Most people experience mild to moderate effects like cold-like symptoms, cough, fever, rash, or some dizziness — these are common and often manageable. The ones to act on immediately are: yellowing of your skin or eyes, dark urine, or severe stomach pain (signs of liver damage); a severe or blistering rash especially with fever, mouth sores, or swollen face (a serious allergic skin reaction); or chest pain or shortness of breath. Don't wait to see if those serious symptoms pass — contact your doctor or emergency services right away.

Will my other HIV medications or any supplements interfere with maraviroc?

▾
Yes — this is really important. Some HIV drugs and other medications can either raise or lower the amount of maraviroc in your blood, which changes the dose you need. For example, many HIV protease inhibitors will increase maraviroc levels, while drugs like efavirenz or rifampin can lower them. St. John's Wort herbal supplement is specifically not recommended because it can drop your maraviroc levels low enough to cause treatment failure. Always keep your prescriber and pharmacist updated on everything you take, including supplements, so your dose is set correctly.

Is it safe to take maraviroc if I'm pregnant or want to breastfeed?

▾
If you're pregnant or planning to become pregnant, talk to your doctor right away. There's a pregnancy registry (the Antiretroviral Pregnancy Registry) that tracks outcomes — your doctor can enroll you by calling 1-800-258-4263. Breastfeeding is not recommended while taking maraviroc because HIV can be passed to your baby through breast milk. Your care team will help you find the safest plan for you and your baby.

Is Maraviroc available over the counter?

▾
No. Maraviroc is a prescription medicine: every Maraviroc product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Maraviroc first available?

▾
The earliest FDA record we hold for Maraviroc is from 2007: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Maraviroc was first used.

Who makes Maraviroc?

▾
8 companies currently list Maraviroc products in the FDA's NDC Directory, including A-S Medication Solutions, ViiV Healthcare Company, A2A Integrated Pharmaceuticals. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Maraviroc on HelloPharmacist

📊Maraviroc supplement interactions168 checked — ranked by severity 🌿Drug & Supplement CheckerMaraviroc vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Maraviroc NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Maraviroc Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Maraviroc forms and strengths (how it comes)

Maraviroc is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Selzentry
How this form is used
What it may be used for
  • Selzentry tablets are used to treat CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2 kg, in combination with other antiretroviral agents
  • Maraviroc tablets are used to treat CCR5-tropic HIV-1 infection in adults and pediatric patients aged 2 years and older weighing at least 10 kg, in combination with other antiretroviral agents
Important instructions
  • Both Selzentry and Maraviroc tablets are taken by mouth twice daily and may be taken with or without food
  • Selzentry tablets: assess children's ability to swallow tablets before prescribing; if a child cannot reliably swallow, use the Selzentry oral solution instead
  • Maraviroc tablets: assess children's ability to swallow tablets before prescribing; prescribe the oral solution formulation if the child cannot reliably swallow
  • The dose for both Selzentry and Maraviroc tablets is adjusted based on other HIV medications being taken — always follow your prescriber's instructions
Available strengths 2 strengths
150 mg 300 mg
23 FDA-listed product records ⓘ

Maraviroc on the U.S. market: products, makers and brands

How Maraviroc appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

8 companies list 18 Maraviroc product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2007. Brand names on the directory include Selzentry; the rest are generics.

1
Dose forms ⓘ
8
Labelers (makers, repackagers, distributors)
2
Brand names
18
FDA-listed product records ⓘ
2007
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (8) · Kit (4) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

A-S Medication Solutions17%
ViiV Healthcare Company17%
A2A Integrated Pharmaceuticals11%
Camber Pharmaceuticals, Inc.11%
Navinta LLC11%
XLCare Pharmaceuticals Inc.11%
Other makers22%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Maraviroc is used (Medicaid data)

A general measure of how commonly Maraviroc is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Maraviroc is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

1,074
Medicaid prescriptions filled (Q1–Q4 2025)
$1.6M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Maraviroc prescribed? Of the 1,601 medications we measure, Maraviroc ranks #1,273 by Medicaid prescriptions — more than 20% of them.

Where Maraviroc ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #1,273 of 1,601
#1,268 Cefiderocol Injection 1,141 Rx #1,269 Anagrelide 1,137 Rx #1,270 Zidovudine 1,095 Rx #1,271 Ravulizumab-cwvz Injec... 1,078 Rx #1,272 Remdesivir Injection 1,078 Rx #1,273 Maraviroc 1,074 Rx #1,274 Olodaterol Oral Inhala... 1,072 Rx #1,275 Degarelix Injection 1,065 Rx #1,276 Ganaxolone 1,063 Rx #1,277 Binimetinib 1,054 Rx #1,278 Belzutifan 1,047 Rx

Utilization by Maraviroc product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 150 mg oral tablet is the most-dispensed Maraviroc product — about 50% of these Medicaid prescriptions.

maraviroc 150 MG Oral Tablet Most dispensed

537 Medicaid prescriptions (Q1–Q4 2025) 50% of Maraviroc prescriptions shown $840,352 gross reimbursement (before rebates) ≈ $1,565 per prescription (gross)

Summed across the 3 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 728223

maraviroc 300 MG Oral Tablet

537 Medicaid prescriptions (Q1–Q4 2025) 50% of Maraviroc prescriptions shown $757,508 gross reimbursement (before rebates) ≈ $1,411 per prescription (gross)

Summed across the 3 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 728225

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Maraviroc, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 6 of 19 listed Maraviroc NDCs with Medicaid activity.

Compare Maraviroc products

A representative set of FDA-listed product records for Maraviroc — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 18 of 18 products — FDA National Drug Code Directory. See every product, package size and price: browse all 18 Maraviroc NDCs →

Maraviroc recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Maraviroc recalls since July 2021.

✅No Maraviroc recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Maraviroc RxCUI 620216 2 dose forms · 5 strengths
  1. Dose form (SCDF) Oral Solution RxCUI 1857920 No current FDA listing
    Clinical drug / strength (SCD) 20 MG/ML RxCUI 1857921
  2. Dose form (SCDF) Oral Tablet RxCUI 728222 In current FDA listings
    Clinical drug / strength (SCD) 25 MG RxCUI 1857911 75 MG RxCUI 1857915 150 MG RxCUI 728223 300 MG RxCUI 728225

Look up RxCUI 620216 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Maraviroc costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet, Film Coated · Oral 150 mg $9.15 per tablet NDC details & price history
Tablet, Film Coated · Oral 300 mg $6.34 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Maraviroc brand names

Maraviroc is sold under one brand name in the FDA directory — Selzentry. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Selzentry

Who makes Maraviroc: manufacturers and labelers

8 companies list Maraviroc products with the FDA. By number of product records, the largest are A-S Medication Solutions, ViiV Healthcare Company, A2A Integrated Pharmaceuticals. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

A-S Medication Solutions 3 ViiV Healthcare Company 3 A2A Integrated Pharmaceuticals 2 Camber Pharmaceuticals, Inc. 2 Navinta LLC 2 XLCare Pharmaceuticals Inc. 2 Zydus Pharmaceuticals USA Inc. 2 i3 Pharmaceuticals, LLC 2

Maraviroc drug class (RxNorm)

Maraviroc belongs to the CCR5 Co-receptor Antagonist class.

Pharmacologic class CCR5 Co-receptor Antagonist
Drug family (ATC) Other antivirals
How it works Chemokine Co-receptor 5 Antagonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Maraviroc page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Sep 26, 2022
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Maraviroc.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Maraviroc after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
11
Finished products in the current FDA directory
18
Companies listing them (makers, repackagers, distributors)
8
FDA labeler codes behind them ⓘ
8
Linked representative label ⓘ
ViiV Healthcare Company
Linked label effective
Sep 26, 2022
Composite sections available
28
Linked SPL Set ID
46f30ac5-c96b-429e-976d-8c5ee1c0761b
Linked SPL Document ID
c3a27122-8cd6-4889-a1ef-7ef629c270b3
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. ViiV Healthcare Company is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →